Smyth R L, Higenbottam T W, Scott J P, Wallwork J
Heart-Lung Transplant Research Unit, Papworth Hospital, Cambridge, U.K.
Respir Med. 1989 Nov;83(6):459-66. doi: 10.1016/s0954-6111(89)80126-x.
Over the last eight years a completely new form of treatment has been introduced for end-stage pulmonary vascular disease and chronic lung disease, including cystic fibrosis. Lung transplantation and heart-lung transplantation have moved from an experimental and innovative stage to clinical treatments. The exclusion criteria for selecting potential recipients have become relaxed whilst preservation techniques have improved to allow ischaemic times of donor organs to be extended beyond 4 h. Monitoring of graft function with daily spirometry and use of transbronchial lung biopsy have enabled early diagnosis of lung rejection or infection and thus effective treatment. Lung transplantation and heart-lung transplantation, by their success, are providing new insight into lung disease and pulmonary physiology.
在过去八年中，一种全新的治疗方式已被引入用于治疗终末期肺血管疾病和慢性肺部疾病，包括囊性纤维化。肺移植和心肺移植已从实验性和创新性阶段进入临床治疗阶段。选择潜在受者的排除标准已放宽，同时保存技术有所改进，使供体器官的缺血时间能够延长至4小时以上。通过每日肺量测定监测移植肺功能以及使用经支气管肺活检能够早期诊断肺排斥或感染，从而进行有效治疗。肺移植和心肺移植的成功为肺部疾病和肺生理学提供了新的见解。
